Table 1. Clinicopathologic characteristics of subjects in this study.

Variables	N (%)
Number	103
Age, y
Median	26
Mean ± SD	26±2.9
Range	11–30
Sex
Male	45 (43.7)
Female	58 (56.3)
Smoking history
Smoker	18 (17.5)
Male	17 (94.4)
Female	1 (5.6)
Current/former	85 (82.5)
Family history of tumor
Yes	23 (22.3)
No	80 (77.7)
Tumor location
RUL	22 (21.4)
RML	4 (3.9)
RLL	22 (21.4)
LUL	14 (13.6)
LLL	28 (27.2)
RUL + RLL	2 (1.9)
RML + RLL	5 (4.9)
LUL + LLL	2 (1.9)
Main bronchus/trachea	4 (3.9)
Laterality
Left	44 (42.7)
Right	55 (53.4)
Other	4 (3.9)
Tumor size (cm)
0–2	60 (58.3)
2–3	17 (16.5)
3–5	20 (19.4)
5–7	4 (3.9)
>7	2 (1.9)
Histological type
AC	51 (49.5)
SCLC	1 (1.0)
LCC	1 (1.0)
ACC	2 (1.9)
MC	11 (10.7)
CTs	8 (7.8)
SP	1 (1.0)
CS	3 (2.9)
PBACC	1 (1.0)
AAH	2 (1.9)
EMC	2 (1.9)
IMT	4 (3.9)
MTs	16 (15.5)
EGFR in AC
Positive	10 (19.6)
Negative	3 (5.9)
Unknown	38 (74.5)
ALK in AC
Positive	3 (5.9)
Negative	10 (19.6)
Unknown	38 (74.5)
Clinical stage
0	7 (6.8)
IA	36 (35.0)
IB	13 (12.6)
IIA	5 (4.9)
IIB	6 (5.8)
IIIA	10 (9.7)
Unknown	26 (25.2)

SD, standard deviation; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; AC, adenocarcinoma; SCLC, small cell lung cancer; LCC, large cell carcinoma; ACC, adenoid cystic carcinoma; MC, mucoepidermoid carcinoma; CTs, carcinoid tumors; SP, sclerosing pneumocytoma; CS, carcinosarcoma; PBACC, primary bronchial acinar cell carcinoma; AAH, atypical adenomatous hyperplasia; EMC, epithelial-myoepithelial carcinoma; IMT, inflammatory myofibroblastic tumor; MTs, metastatic tumors; EGFR, endothelial growth factor receptor; ALK, anaplastic lymphoma kinase.